Protein delivery of an artificial transcription factor restores widespread Ube3a expression in an angelman syndrome mouse brain

Barbara J. Bailus, Benjamin Pyles, Michelle M. Mcalister, Henriette O'Geen, Sarah H. Lockwood, Alexa N. Adams, Jennifer Trang T Nguyen, Abigail Yu, Robert F Berman, David Segal

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Angelman syndrome (AS) is a neurological genetic disorder caused by loss of expression of the maternal copy of UBE3A in the brain. Due to brain-specific genetic imprinting at this locus, the paternal UBE3A is silenced by a long antisense transcript. Inhibition of the antisense transcript could lead to unsilencing of paternal UBE3A, thus providing a therapeutic approach for AS. However, widespread delivery of gene regulators to the brain remains challenging. Here, we report an engineered zinc finger-based artificial transcription factor (ATF) that, when injected i.p. or s.c., crossed the blood-brain barrier and increased Ube3a expression in the brain of an adult mouse model of AS. The factor displayed widespread distribution throughout the brain. Immunohistochemistry of both the hippocampus and cerebellum revealed an increase in Ube3a upon treatment. An ATF containing an alternative DNA-binding domain did not activate Ube3a. We believe this to be the first report of an injectable engineered zinc finger protein that can cause widespread activation of an endogenous gene in the brain. These observations have important implications for the study and treatment of AS and other neurological disorders.

Original languageEnglish (US)
Pages (from-to)548-555
Number of pages8
JournalMolecular Therapy
Volume24
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Angelman Syndrome
Transcription Factors
Brain
Proteins
Zinc Fingers
Nervous System Diseases
Genomic Imprinting
Inborn Genetic Diseases
Regulator Genes
Blood-Brain Barrier
Cerebellum
Transcriptional Activation
Hippocampus
Therapeutics
Immunohistochemistry
Mothers
Injections
DNA

ASJC Scopus subject areas

  • Medicine(all)
  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Protein delivery of an artificial transcription factor restores widespread Ube3a expression in an angelman syndrome mouse brain. / Bailus, Barbara J.; Pyles, Benjamin; Mcalister, Michelle M.; O'Geen, Henriette; Lockwood, Sarah H.; Adams, Alexa N.; Nguyen, Jennifer Trang T; Yu, Abigail; Berman, Robert F; Segal, David.

In: Molecular Therapy, Vol. 24, No. 3, 01.03.2016, p. 548-555.

Research output: Contribution to journalArticle

Bailus, Barbara J. ; Pyles, Benjamin ; Mcalister, Michelle M. ; O'Geen, Henriette ; Lockwood, Sarah H. ; Adams, Alexa N. ; Nguyen, Jennifer Trang T ; Yu, Abigail ; Berman, Robert F ; Segal, David. / Protein delivery of an artificial transcription factor restores widespread Ube3a expression in an angelman syndrome mouse brain. In: Molecular Therapy. 2016 ; Vol. 24, No. 3. pp. 548-555.
@article{f442cdfa28c64cc4ae230c636b342b80,
title = "Protein delivery of an artificial transcription factor restores widespread Ube3a expression in an angelman syndrome mouse brain",
abstract = "Angelman syndrome (AS) is a neurological genetic disorder caused by loss of expression of the maternal copy of UBE3A in the brain. Due to brain-specific genetic imprinting at this locus, the paternal UBE3A is silenced by a long antisense transcript. Inhibition of the antisense transcript could lead to unsilencing of paternal UBE3A, thus providing a therapeutic approach for AS. However, widespread delivery of gene regulators to the brain remains challenging. Here, we report an engineered zinc finger-based artificial transcription factor (ATF) that, when injected i.p. or s.c., crossed the blood-brain barrier and increased Ube3a expression in the brain of an adult mouse model of AS. The factor displayed widespread distribution throughout the brain. Immunohistochemistry of both the hippocampus and cerebellum revealed an increase in Ube3a upon treatment. An ATF containing an alternative DNA-binding domain did not activate Ube3a. We believe this to be the first report of an injectable engineered zinc finger protein that can cause widespread activation of an endogenous gene in the brain. These observations have important implications for the study and treatment of AS and other neurological disorders.",
author = "Bailus, {Barbara J.} and Benjamin Pyles and Mcalister, {Michelle M.} and Henriette O'Geen and Lockwood, {Sarah H.} and Adams, {Alexa N.} and Nguyen, {Jennifer Trang T} and Abigail Yu and Berman, {Robert F} and David Segal",
year = "2016",
month = "3",
day = "1",
doi = "10.1038/mt.2015.236",
language = "English (US)",
volume = "24",
pages = "548--555",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Protein delivery of an artificial transcription factor restores widespread Ube3a expression in an angelman syndrome mouse brain

AU - Bailus, Barbara J.

AU - Pyles, Benjamin

AU - Mcalister, Michelle M.

AU - O'Geen, Henriette

AU - Lockwood, Sarah H.

AU - Adams, Alexa N.

AU - Nguyen, Jennifer Trang T

AU - Yu, Abigail

AU - Berman, Robert F

AU - Segal, David

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Angelman syndrome (AS) is a neurological genetic disorder caused by loss of expression of the maternal copy of UBE3A in the brain. Due to brain-specific genetic imprinting at this locus, the paternal UBE3A is silenced by a long antisense transcript. Inhibition of the antisense transcript could lead to unsilencing of paternal UBE3A, thus providing a therapeutic approach for AS. However, widespread delivery of gene regulators to the brain remains challenging. Here, we report an engineered zinc finger-based artificial transcription factor (ATF) that, when injected i.p. or s.c., crossed the blood-brain barrier and increased Ube3a expression in the brain of an adult mouse model of AS. The factor displayed widespread distribution throughout the brain. Immunohistochemistry of both the hippocampus and cerebellum revealed an increase in Ube3a upon treatment. An ATF containing an alternative DNA-binding domain did not activate Ube3a. We believe this to be the first report of an injectable engineered zinc finger protein that can cause widespread activation of an endogenous gene in the brain. These observations have important implications for the study and treatment of AS and other neurological disorders.

AB - Angelman syndrome (AS) is a neurological genetic disorder caused by loss of expression of the maternal copy of UBE3A in the brain. Due to brain-specific genetic imprinting at this locus, the paternal UBE3A is silenced by a long antisense transcript. Inhibition of the antisense transcript could lead to unsilencing of paternal UBE3A, thus providing a therapeutic approach for AS. However, widespread delivery of gene regulators to the brain remains challenging. Here, we report an engineered zinc finger-based artificial transcription factor (ATF) that, when injected i.p. or s.c., crossed the blood-brain barrier and increased Ube3a expression in the brain of an adult mouse model of AS. The factor displayed widespread distribution throughout the brain. Immunohistochemistry of both the hippocampus and cerebellum revealed an increase in Ube3a upon treatment. An ATF containing an alternative DNA-binding domain did not activate Ube3a. We believe this to be the first report of an injectable engineered zinc finger protein that can cause widespread activation of an endogenous gene in the brain. These observations have important implications for the study and treatment of AS and other neurological disorders.

UR - http://www.scopus.com/inward/record.url?scp=84960399229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960399229&partnerID=8YFLogxK

U2 - 10.1038/mt.2015.236

DO - 10.1038/mt.2015.236

M3 - Article

VL - 24

SP - 548

EP - 555

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -